RESONANCE is a Phase I/II, multicenter trial. Phase I is open-label and is designed to determine the safety profile and tolerability of medicinal cannabis in people with advanced cancer by evaluating clinical outcomes and a pharmacokinetic profile.

Phase II is a double-blind, randomized, placebo-controlled trial designed to determine the impact of medicinal cannabis on quality of life and symptom control, covering pain, anorexia, anxiety, sleep, nausea, treatment satisfaction, toxicity, and caregiver burden, all measured with validated instruments.

The authors state their rationale directly: medicinal cannabis is increasingly used in cancer care despite limited high-quality evidence to inform practice, and legalization has outpaced high-quality research on cancer symptom outcomes, leaving patients and prescribers with real uncertainty.

A staged design, safety and pharmacokinetics first, then a randomized, blinded efficacy question, is the standard structure for building evidence responsibly rather than skipping to broad clinical claims.

This publication is a trial protocol, not a results paper. It describes the design, population, phases, and outcome measures for a study that is underway; it does not report whether medicinal cannabis improved, worsened, or had no effect on any of the quality-of-life or symptom domains it plans to measure.

Publications of this type are meant to be read as a description of the question being asked and how rigorously it will be tested, not as an early signal of the answer.

The trial is multicenter, and the authors note that the findings have the potential to inform clinical practice and reduce decisional uncertainty for prescribers and patients, given the very large number of people who die of advanced cancer worldwide each year.

That framing describes the trial’s intended significance if it succeeds. It is a statement of the question’s importance, not a claim that the trial has already demonstrated an effect at that scale.

The next milestones to track are the Phase I safety, tolerability, and pharmacokinetic results, followed by the Phase II quality-of-life and symptom-control outcomes from the randomized, placebo-controlled comparison.

The trial is listed on the Australian New Zealand Clinical Trials Registry under ACTRN12619001534178, which is the reference point for checking recruitment status and eventual results reporting.

Medical cannabis use in advanced cancer and palliative care has expanded well ahead of controlled outcome data, a gap the authors name explicitly as their motivation for the trial. Protocol publications like this one are how that gap eventually gets closed, provided the subsequent Phase I and Phase II results are published and reviewed with the same scrutiny.

A staged safety-then-efficacy design, using validated multi-domain instruments rather than a single symptom score, reflects a more rigorous standard than much of the existing observational literature on cannabis in cancer care.

Patients with advanced cancer ask me about cannabis constantly, usually after they have already started using it based on a friend’s experience or something they read online. What I want for them is not more anecdote; it is exactly this kind of staged, validated-instrument trial that treats their quality of life as something worth measuring rigorously rather than assuming.

I will be watching for the Phase I safety and pharmacokinetic results first, because that is the responsible order, and I will not be citing this protocol as evidence of benefit to any patient in the meantime. A well-designed question is not the same as an answer.

Four questions to ask before summarizing this protocol